Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug. Kisunla (donanemab) is the second in a new generation of ...

INDIANAPOLIS, Oct. 11, 2024 Based on a Nikkei Asia report, pharmaceutical giant, Eli Lilly (LLY, Financial) expects its weight-loss drug Zepbound to get regulatory clearance in Japan by mid-2025.

Eli Lilly’s (NYSE:LLY) treatment for early Alzheimer's disease has been approved for use in Japan. Kisunla (donanemab-azbt), ...

Eli Lilly & Co. Inc. said Tuesday the Japanese regulator has approved its Kisunla treatment for adults with early symptomatic ...

Eli Lilly has won Japanese regulatory approval for Kisunla, marking the second major market where the new Alzheimer's disease drug has received a green light. Eli Lilly on Tuesday said Japan's ...

From falling oil prices after Israel's retaliatory strike on Iran to Eli Lilly’s weight-loss drug launch in Hong Kong, here’s ...

Eli Lilly reported weaker results for the latest ... indexes were mostly lower in Europe and Asia despite a 1% rise for Japan’s Nikkei 225 as the Bank of Japan began a two-day policy meeting.

INDIANAPOLIS, Oct. 11, 2024 Based on a Nikkei Asia report, pharmaceutical giant, Eli Lilly (LLY, Financial) expects its weight-loss drug Zepbound to get regulatory clearance in Japan by mid-2025. In ...